Mach7 TechnologiesASX:M7T +3.39%29 Return-on-Tangible-Equity is -54.05% as of Dec. 2025. GuruFocus rates ASX:M7T with a GF Score™ of 29/100 and a GF Value™ of A$0.84 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 579 Healthcare Providers & Services companies, Mach7 Technologies ranks worse than 87.39% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Mach7 Technologies's annualized net income for the quarter that ended in Dec. 2025 was A$-11.50 Mil. Mach7 Technologies's average shareholder tangible equity for the quarter that ended in Dec. 2025 was A$21.27 Mil. Therefore, Mach7 Technologies's annualized Return-on-Tangible-Equity for the quarter that ended in Dec. 2025 was -54.05%.
The historical rank and industry rank for Mach7 Technologies's Return-on-Tangible-Equity or its related term are showing as below:
ASX:M7T'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -43.68 Med: -25.03 Max: 0.73
Current: -43.68
During the past 13 years, Mach7 Technologies's highest Return-on-Tangible-Equity was 0.73%. The lowest was -43.68%. And the median was -25.03%.
ASX:M7T's Return-on-Tangible-Equity is ranked worse than 87.39% of 579
companies
in the Healthcare Providers & Services industry
Industry Median: 10.13
vs ASX:M7T: -43.68
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Mach7 Technologies Return-on-Tangible-Equity Related Terms
Mach7 Technologies Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Mach7 Technologies's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:M7T vs VEEV, BTSG, TEM: Return-on-Tangible-Equity Comparison
For the Health Information Services subindustry, Mach7 Technologies's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Mach7 Technologies Return-on-Tangible-Equity vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Mach7 Technologies's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Mach7 Technologies's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is two times the semi-annual (Dec. 2025) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of -54.05% mean?
Mach7 Technologies (ASX:M7T) has a Return-on-Tangible-Equity of -54.05% as of Dec. 2025. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Mach7 Technologies and its competitors. According to the industry distribution chart, Mach7 Technologies ranks #506 out of 579 companies in the Healthcare Providers & Services industry, placing it in the top 87.4%.
Is Mach7 Technologies' Return-on-Tangible-Equity too high?
Mach7 Technologies' current Return-on-Tangible-Equity is -54.05%. Based on the distribution chart, Mach7 Technologies ranks #506 out of 579 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, Mach7 Technologies has a GF Score™ of 29/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Mach7 Technologies' Return-on-Tangible-Equity compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, Mach7 Technologies ranks #506 out of 579 companies for Return-on-Tangible-Equity. This places Mach7 Technologies in the lower half of its industry. The industry median Return-on-Tangible-Equity is 10.13. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Healthcare Providers & Services company?
The median Return-on-Tangible-Equity among Healthcare Providers & Services companies is 10.13, based on 579 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Mach7 Technologies and its competitors. For the Healthcare Providers & Services industry, the median Return-on-Tangible-Equity is 10.13 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Mach7 Technologies's current Return-on-Tangible-Equity is -54.05%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mach7 Technologies stock overvalued right now?
Based on GuruFocus' analysis, Mach7 Technologies (ASX:M7T) is currently considered Possible Value Trap. The stock's GF Value™ is A$0.84, compared to a current price of A$0.31 — trading 63.7% below its estimated fair value. The current Return-on-Tangible-Equity is -54.05%. Mach7 Technologies' overall GF Score™ is 29/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Mach7 Technologies (ASX:M7T), the current Return-on-Tangible-Equity is -54.05% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Mach7 Technologies (ASX:M7T) Overvalued in 2026?
Based on GuruFocus' analysis, Mach7 Technologies stock appears to be undervalued.
The current stock price of A$0.31 is trading 63.7% below its estimated GF Value™ of A$0.84.
GuruFocus considers Mach7 Technologies to be Possible Value Trap.
Key valuation signals for ASX:M7T:
Return-on-Tangible-Equity: -54.05%
GF Value™: A$0.84 vs. price of A$0.31 (63.7% below fair value)
No single metric tells the full story. See the ASX:M7T stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Mach7 Technologies Ltd is a healthcare software company focused on enterprise imaging infrastructure. The company's vendor neutral platform enables health systems to manage, access, and exchange medical imaging data across departments, sites, and vendors. It serves across North America, Asia-Pacific, and the Middle East, with deployments ranging from academic medical centres to multi-site health networks. A substantial part of revenue is derived in the form of Subscription revenue. Geographically, it derives a majority of its revenue from North America.
29GF Score
Get the complete analysis for ASX:M7T
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:M7T has been successfully added to your 
